ArticleHeliyon2024
Identification and verification of a PANoptosis-related long noncoding ribonucleic acid signature for predicting the clinical outcomes and immune landscape in lung adenocarcinoma.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Article
- Epigenetic regulation of PANoptosis: DNA methylation, histone modifications and non-coding RNAs.EXCLI journal · 2026Review
- A disulfidptosis-related gene signature predicts prognosis and immune-metabolic landscape in multiple myeloma.British journal of haematology · 2025Article
- Single-cell hdWGCNA identifies ICI-related-colitis key CD8 + T cells linked to immunotherapy response and prognosis in colon cancer.Discover oncology · 2025Article
- Immune infiltration and drug treatment response of angiogenesis-related LncRNA in lung adenocarcinoma.Medicine · 2025Article
- Comprehensive assessment of disulfidptosis-related long non-coding RNA index as biomarkers for predicting clinical outcomes and immune microenvironment in pancreatic cancer.Translational cancer research · 2025Article
- Development of a PANoptosis-related LncRNAs for prognosis predicting and immune infiltration characterization of gastric Cancer.Scientific reports · 2025Article
- A novel telomere-associated genes signature for the prediction of prognosis and treatment responsiveness of hepatocellular carcinoma.Biological procedures online · 2025Article
- Identification and validation of PANoptosis-related LncRNAs prognosis system in hepatocellular carcinoma.Scientific reports · 2025Article
- PANoptosis-related genes in the prognosis and immune landscape of hepatocellular carcinoma.Immunologic research · 2025Article
- Exploring the role of ELOVLs family in lung adenocarcinoma based on bioinformatic analysis and experimental validation.BMC cancer · 2025Article
- Circadian rhythm-based prognostic features predict immune infiltration and tumor microenvironment in molecular subtypes of hepatocellular carcinoma.Open life sciences · 2025Article
- Article
- An Integrated Analysis of HAVCR1 with a Focus on Immunological and Prognostic Roles in Breast Cancer.Cancer informatics · 2025Article
- DNA methylation-driven gene-based drug response prediction model for liver cancer: The critical role of GLS.PloS one · 2025Article
- Development of Novel PANoptosis-Related Gene Signatures to Predict the Prognosis of Patients With Stomach Adenocarcinoma.Human mutation · 2025Article
- A novel disulfidptosis-related LncRNA prognostic risk model: predicts the prognosis, tumor microenvironment and drug sensitivity in esophageal squamous cell carcinoma.BMC gastroenterology · 2024Article
- Pyroptosis-related lncRNAs are potential biomarkers for predicting prognoses and immune landscapes in patients with gastric adenocarcinoma.Discover oncology · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PANoptosis is a type of programmed cell death (PCD) characterised by apoptosis, necroptosis and pyroptosis. Long non-coding ribonucleic acids (lncRNAs) are participating in the malignant behaviour of tumours regulated by PCD. Nevertheless, the function of PANoptosis-associated lncRNAs in lung adenocarcinoma remains to be investigated. In this work, a PANoptosis-related lncRNA signature (PRLSig) was developed based on the least absolute shrinkage and selection operator algorithm. The stability and fitness of PRLSig were confirmed by systematic evaluation of Kaplan-Meier, Cox analysis algorithm, receiver operating characteristic analysis, stratification analysis. In addition, ESTIMATE, single sample gene set enrichment analysis, immune checkpoints and the cancer immunome database confirmed the predictive value of the PRLSig in immune microenvironment and helped to identify populations for which immunotherapy is advantageous. The present research provides novel insights to facilitate risk stratification and optimise personalised treatment for LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.